NCT04642430View on ClinicalTrials.gov

COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation

PHASE4RecruitingINTERVENTIONAL
Enrollment

3,018

Participants

Timeline

Start Date

July 6, 2021

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Atrial Fibrillation
Interventions
DRUG

Apixaban

Refer to Apixaban group

DRUG

Rivaroxaban

Refer to Rivaroxaban group

Trial Locations (8)

V8Z 0B9

RECRUITING

Victoria Cardiac Arrhythmia Trials, Victoria

Unknown

RECRUITING

QEII Health Science Centre, Halifax

RECRUITING

Kingston General Hospital, Kingston

RECRUITING

University Ottawa Heart Institute, Ottawa

NOT_YET_RECRUITING

CHU de Quebec - Université Laval, Laval

K1H 8L6

RECRUITING

The Ottawa Hospital - General Campus, Ottawa

J8T 4J3

RECRUITING

CISSS de l'Outaouais, Gatineau

H3L 1K5

NOT_YET_RECRUITING

Ciusss Nim, Montreal

Sponsors
All Listed Sponsors
collaborator

Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network

NETWORK

collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

Ottawa Hospital Research Institute

OTHER